First administration of PB004 to animals

On June 7th, 2022, Pure Biologics commenced its first pilot preclinical study in the PB004 project developing a potential drug for the treatment of solid tumors and leukemia.

News

Inquiries

16 December

2020

Pure Biologics debut on the WSE Main Market – news

News on the debut of Pure Biologics on the WSE Main Market in key business and industry media.

Debut on the WSE Main Market, 14.12.2020 (on-line)

11 December

2020

Debut on the WSE Main Market, 14.12.2020 (on-line)

Pure Biologics debut on the Regulated Market of the Warsaw Stock Exchange.

25 November

2020

Filip Jeleń on “Parkiet TV”

The guest of Grzegorz Siemionczyk's #PROSTOzPARKIET program was Filip Jeleń, CEO of Pure Biologics.

Webinar organized by “Strefa Inwestorów” with Pure Biologics, Tuesday 24/11/2020

21 November

2020

Webinar organized by “Strefa Inwestorów” with Pure Biologics, Tuesday 24/11/2020

Webinar organized by "Strefa Inwestorów" with Pure Biologics, Tuesday 24/11/2020

“Nasz biznes zależy od ludzi i kapitału, a nie od miejsca” – Puls Biznesu article

19 November

2020

“Nasz biznes zależy od ludzi i kapitału, a nie od miejsca” – Puls Biznesu article

An interview with Filip Jeleń, Romuald Harwas and Przemysł Jurek.

9 October

2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/5/20 09.10.2020

17 June

2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/4/20 17.06.2020

10 April

2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/3/20 10.04.2020

25 January

2020

Zapytanie Ofertowe – PB/MAGBBRIS/0/2/20 25.01.2020

21 January

2020